Clearside Biomedical, Inc. (CLSD): Price and Financial Metrics


Clearside Biomedical, Inc. (CLSD)

Today's Latest Price: $1.89 USD

0.19 (-9.13%)

Updated May 28 8:00pm

Add CLSD to Watchlist
Sign Up

Overall POWR Rating


POWR Components:

 Trade Grade  Buy & Hold Grade  Peer Grade  Industry Rank


Industry Rank:

Ranked of 214 in Medical - Pharmaceuticals

See all "A" rated Strong Buy stocks

CLSD Stock Summary

  • With a year-over-year growth in debt of -45.32%, Clearside Biomedical Inc's debt growth rate surpasses only 5.98% of about US stocks.
  • Revenue growth over the past 12 months for Clearside Biomedical Inc comes in at 8,200%, a number that bests 99.77% of the US stocks we're tracking.
  • In terms of volatility of its share price, CLSD is more volatile than 93.33% of stocks we're observing.
  • Stocks with similar financial metrics, market capitalization, and price volatility to Clearside Biomedical Inc are MDWD, CLXT, ZLAB, LIFE, and STML.
  • CLSD's SEC filings can be seen here. And to visit Clearside Biomedical Inc's official web site, go to www.clearsidebio.com.
CLSD Daily Price Range
CLSD 52-Week Price Range

CLSD Stock Price Chart More Charts


CLSD Price/Volume Stats

Current price $1.89 52-week high $4.13
Prev. close $2.08 52-week low $0.56
Day low $1.86 Volume 451,600
Day high $2.09 Avg. volume 814,576
50-day MA $1.87 Dividend yield N/A
200-day MA $1.74 Market Cap 84.80M

Clearside Biomedical, Inc. (CLSD) Company Bio


Clearside Biomedical, a biopharmaceutical company, develops drug therapies to treat chronic blinding diseases of the eye. The company was founded in 2011 and is based in Alpharetta, Georgia


CLSD Latest News Stream


Event/TimeNews Detail
Loading, please wait...

CLSD Latest Social Stream


Loading social stream, please wait...

View Full CLSD Social Stream

Latest CLSD News From Around the Web

Below are the latest news stories about Clearside Biomedical Inc that investors may wish to consider to help them evaluate CLSD as an investment opportunity.

Will Clearside Biomedical, Inc. (CLSD) Report Negative Q1 Earnings? What You Should Know

Clearside Biomedical, Inc. (CLSD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Investment Research | May 6, 2020

Clearside Biomedical, Inc. (CLSD) Expected to Beat Earnings Estimates: Can the Stock Move Higher?

Clearside Biomedical, Inc. (CLSD) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Investment Research | March 4, 2020

The Daily Biotech Pulse: EyePoint In-Licenses Eye Disorder Drug, BioMarin CFO Quits, Rockwell Medical To Offer Shares

Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech stocks that hit 52-week highs Feb. 3.) Acceleron Pharma Inc (NASDAQ: XLRN ) Aptose Biosciences Inc (NASDAQ: APTO ) Catalent Inc (NYSE: CTLT ) ( announced a deal to buy cell and gene therapy CDMO MasTherCell and forecast-beating second quarter results) ChemoCentryx Inc (NASDAQ: CCXI ) Clearside Biomedical Inc (NASDAQ: CLSD ) Fate Therapeutics Inc (NASDAQ: FATE ) ITAMAR MED LTD/S ADR (NASDAQ: ITMR ) Molecular Templates Inc (NASDAQ: MTEM ) Orgenesis Inc (NASDAQ: ORGS ) (announced sale of subsidiary MasTherCell to Catalent) Profound Medical Corp (NASDAQ: PROF ) Reata Pharmaceuticals Inc (NASDAQ: RETA ) Repligen Corporation (NASDAQ: RGEN ) Theravance Biopharma Inc (NASDAQ: TBPH ) Down...

Benzinga | February 4, 2020

Bausch Health and Clearside Biomedical Announce Publication of PIVOTAL Phase 3 Data ON XIPERETM (triamcinolone acetonide suprachoroidal injectable suspension) in Ophthalmology

LAVAL, Quebec and ALPHARETTA, Ga., Jan. 28, 2020 /PRNewswire/ -- Bausch Health Companies Inc. (NYSE/TSX: BHC) ("Bausch Health") and Bausch + Lomb, its leading global eye health business, and Clearside Biomedical, Inc. (Nasdaq: CLSD), a biopharmaceutical company dedicated to developing and…

PR Newswire | January 28, 2020

The Daily Biotech Pulse: Qiagen Opts To Stay Solo Following Strategic Review, Spectrum Slumps On Negative Data, Microbot Medical To Offer Shares

The following is a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks that hit 52-week highs Dec. 24.) Aimmune Therapeutics Inc (NASDAQ: AIMT ) Applied Genetic Technologies Corp (NASDAQ: AGTC ) Cassava Sciences Inc (NASDAQ: SAVA ) ChemoCentryx Inc (NASDAQ: CCXI ) Clearside Biomedical Inc (NASDAQ: CLSD ) DURECT Corporation (NASDAQ: DRRX ) Eiger Biopharmaceuticals Inc (NASDAQ: EIGR ) Esperion Therapeutics Inc (NASDAQ: ESPR ) Exagen Inc (NASDAQ: XGN ) Forty Seven Inc (NASDAQ: FTSV ) Fulcrum Therapeutics Inc (NASDAQ: FULC ) Global Blood Therapeutics Inc (NASDAQ: GBT ) Harpoon Therapeutics Inc (NASDAQ: HARP ) Horizon Therapeutics PLC (NASDAQ: HZNP ) HEALTH SCIENCES/SH (NASDAQ: IMVT ) Intuitive Surgical, Inc. (NASDAQ: ISRG ) Jazz Pharmac...

Benzinga | December 26, 2019

Read More 'CLSD' Stories Here

CLSD Price Returns

1-mo -0.53%
3-mo -15.63%
6-mo 31.25%
1-year 64.35%
3-year -73.93%
5-year N/A
YTD -34.83%
2019 171.03%
2018 -84.71%
2017 -21.70%
2016 N/A
2015 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!



Page generated in 0.9341 seconds.